Reig Jofre's nutritional supplements line expands its product portfolio
Forté Pharma expands its energy and health segments with the launch of eight references in the French market, as a result of its product development strategy.
Forté Pharma, Reig Jofre’s nutritional supplements line, launches in France, its home market, eight references in the energy and health segments, as a result of its strategy of development and extension of their portfolios in comparison with the weight control segment, with a higher seasonality and exposure to the evolution of consumption in Europe.
Forté Pharma has well-consolidated positioning products in the energy segment such as the Vitalité 4G line, with more than 10 years of market presence and sales leader in its category, which extends its range with Vitalité 4G Shot, concentrated spray in ginseng, guarana, ginger and royal jelly to combat temporary fatigue and lack of energy and with Vitalité 4G Senior enriched with ginkgo biloba tostrengthen brain functions, improve concentration, combat memory loss, promote cerebral blood circulation and also enriched with astragalus, known antioxidant that increases physical and mental endurance, helps to reinforce the defenses and has an anti-aging activity.
Likewise, the jelly line extends its range with Gelée Royale Dynamisant, nutritious and energetic concentrate based on royal jelly, mate, acerola and pollen, designed to strengthen the defenses and combat fatigue.
The energy segment, growing in the market for nutritional supplements in France, reaches sales of more than 170 million euros, of which Forté Pharma contributes 6 million euros, with more than 3,000 points of sale between pharmacies and parapharmacies.
In the health segment, Forté Pharma expands its line of products with five references, Forté Rub, the first nutritional supplement whose unique formula based on chronobiology, combines six natural extracts to combat common cold symptoms through a specific formula for the day to clear respiratory tract, eliminates nasal congestion, avoids coughing and restores energy; and another formula for the night that relieves throat, clears nose and fights fever to improve respiratory comfort and sleep better. Propolis Spray, highly concentrated formula for maximum effectiveness in throat care and Propolis Spray Junior, sweet formula specially adapted for children. Co-Enzyme Q10, potent antioxidant indicated in the cell protection from the harmful effects of free radicals. The range of jelly beans MiniGum for children from three years of age to help them stay in shape and improve their defenses, rest and growth, launches a new reference enriched with fiber to promote intestinal transit.
Nowadays the portfolio of Forte Pharma is organized into four segments: slimming (30% of its total sales), energy (35%), health (22%) and beauty (13%) at the end of September 2017.
Reig Jofre focused much of their efforts on enhancing the geographical diversification of Forte Pharma and expanding its product portfolio through direct support of its marketing strategy.
The positive evolution of energy and health segments in recent years made possible counteract the effect of the contraction suffered by the nutritional supplements industry for weight control in France, so the company will continue to work in this line of development.
In terms of geographic diversification, the presence of the brand in markets outside France went from 22% in 2006 to 33% at the end of 2017. At present, the marketing of Forte Pharma products is conducted mostly in Europe through own sales network. Forte Pharma’s home market, and still today the first market of the brand, is France, which concentrated 67% of sales, followed by Forte Pharma Iberica (Spain and Portugal) and Benelux, with 13% respectively, and 7% in the rest of the world.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.